£1.5M
The Swansea-based diagnostics firm secured £1.5m from a syndicate of investors to support product development and clinical trials.
"We’re pleased to have backed CanSense during this investment round with equity support. Their testing technology shows huge potential, with benefits for NHS backlogs if adopted widely, and we’re glad to support the work of this company as it brings its expertise to Wales’ increasingly strong med-tech sector."
